Sermorelin dosage protocol

What Sermorelin Is

Sermorelin is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analogue (PMID 41880199, PMID 18031173). It is the shortest synthetic peptide known to retain the full biological activity of GHRH (PMID 18031173).

It is composed of 29 amino acids and specifically stimulates growth hormone secretion from the anterior pituitary gland (human, PMID 18031173).

How It Is Thought to Work

As a growth hormone secretagogue, sermorelin activates IGF-1 (insulin-like growth factor 1) signaling pathways (PMID 41490200). It is considered a potent stimulator of both growth hormone and IGF-1 (PMID 32257855).

Laboratory and Human Studies

In human studies, intravenous sermorelin (1 microg/kg bodyweight) has been used as a relatively specific test for diagnosing growth hormone deficiency in children, with fewer false positive growth hormone responses compared to other tests (human, PMID 18031173). Combining intravenous sermorelin with arginine may offer a more specific diagnostic test for adults, which warrants evaluation in children (human, PMID 18031173).

Limited data indicate that once-daily subcutaneous sermorelin (30 microg/kg bodyweight at bedtime) was effective in treating some prepubertal children with idiopathic growth hormone deficiency, showing significant increases in height velocity over 12 months (human, PMID 18031173). Some evidence suggests this effect might be sustained for up to 36 months of continued treatment in a few children (human, PMID 18031173). Sermorelin induced catch-up growth in the majority of growth hormone-deficient children studied, particularly in slow-growing, shorter children with delayed bone and height age (human, PMID 18031173).

Limitations and Regulatory Status

Despite promising preclinical findings for some peptides, there is a general lack of clinical trials for many in orthopedics (PMID 41490200). For sermorelin specifically, the effect of long-term treatment on final adult height is yet to be determined (human, PMID 18031173). There is also a paucity of data on its clinical efficacy and potential complementary role in managing hypogonadal males (human, PMID 32257855).

Sermorelin and its synthetic analogs are prohibited by the World Anti-Doping Agency (WADA) due to their use in performance enhancement (PMID 34665524, PMID 37806509, PMID 41880199). WADA-accredited laboratories have developed sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods to detect sermorelin and its metabolites in urine samples, with detection limits as low as 0.2 ng/mL (PMID 34665524, PMID 37806509).

Key Terms Explained

**Growth hormone-releasing hormone (GHRH)**: A hormone that stimulates the pituitary gland to release growth hormone (PMID 18031173).

**Growth hormone secretagogue (GHS)**: A substance that promotes the secretion of growth hormone (PMID 41490200).

**IGF-1 signaling**: Insulin-like growth factor 1, a hormone similar in molecular structure to insulin that plays an important role in childhood growth and continues to have anabolic effects in adults (PMID 41490200).

**Hypogonadism**: A condition in which the body doesn't produce enough of the hormone testosterone (PMID 32257855).